¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"Negative life event in childhood, unspecified"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 3 ÆäÀÌÁö: 1
¿µ¹® half-life ÇÑ±Û ¹Ý°¨±â
¼³¸í   
  ¾î¶² ¹°ÁúÀÌ ¿ÜºÎÀû ¿äÀÎ, ¶Ç´Â ³»ºÎÀû ¿äÀο¡ ÀÇÇØ¼­ ºÐÇØµÉ °æ¿ì¿¡ ±× ¹°ÁúÀÇ ¿ø·¡ÀÇ ¾ç¿¡¼­ ¹ÝÀÌ µÇ´Â µ¥ °É¸®´Â ½Ã°£.
¿µ¹® childhood diabetes ÇÑ±Û ¼Ò¾Æ´ç´¢º´
¼³¸í   
  ¼Ò¾Æ¿¡ ³ªÅ¸³ª´Â ´ç´¢º´. ´ç´¢º´Àº Àν¶¸° ºÎÁ·À¸·Î Ã¼³» Æ÷µµ´ç ÀÌ¿ëÀÌ ÀúÇϵǾî Åº¼öÈ­¹°-Áö¹æ-´Ü¹éÁú ´ë»ç°¡ ÀåÇØ¸¦ ÀÏÀ¸Å°´Â Áúº´À¸·Î, ¼ºÀÎÇü ´ç´¢º´°ú ¿¬¼ÒÇü ´ç´¢º´ÀÌ ÀÖ´Ù. ¼ºÀÎÇüÀº Àν¶¸°ÀÇ »ó´ëÀû ºÎÁ·, Áï ºñ¸¸À¸·Î ÀÎÇÑ Àν¶¸° °¨¼ö¼ºÀÇ ÀúÇÏ °á°ú Àν¶¸° Çʿ䷮ÀÇ Áõ´ë¿¡¼­ ¿À´Â °ÍÀ̸ç, ¼Ò¾ÆÇü ´ç´¢º´Àº ÀÌÀÚÀÇ ¶û°Ô¸£Çѽº¼¶ º£Å¸(¥â)¼¼Æ÷ÀÇ ÀåÇØ·Î ÀÎÇÑ Àν¶¸°ÀÇ Àý´ëÀû °áÇÌ¿¡¼­ ¿Â´Ù. ¼¼°èº¸°Ç±â±¸(WHO)ÀÇ ±ÇÀåÀ¸·Î 15¼¼ ÀÌÀü¿¡ ¹ßº´Çϴ ´ç´¢º´À» ¸ðµÎ ¼Ò¾Æ´ç´¢º´À̶ó Çϴµ¥, ¾î¸°ÀÌ¿¡°Ôµµ °£È¤ ¼ºÀÎÇü(¶Ç´Â ºñ¸¸Çü) ´ç´¢º´ÀÌ ÀÖÀ¸¹Ç·Î ¼Ò¾Æ´ç´¢º´À̶ó ÇÔÀº ¼Ò¾Æ±â¿¡ ¹ßº´Çϴ ¼Ò¾ÆÇü°ú ¼ºÀÎÇü ´ç´¢º´ÀÇ ÃÑĪÀ̶ó ÇÒ ¼ö ÀÖ´Ù. ÇöÀç±îÁö Åë°è¿¡ ÀÇÇϸé ÀüüÀα¸ÀÇ ¾à 5%´Â ´ç´¢º´À» °¡Áö°í ÀÖÀ¸¸ç, ±× °¡¿îµ¥ ¾à 2%°¡ 15¼¼ ÀÌÀü¿¡ ¹ßº´Çϴ °ÍÀ¸·Î ¾Ë·ÁÁ³´Ù.
¿µ¹® childhood ÇÑ±Û ¾Æµ¿±â, ¼Ò¾Æ±â
¼³¸í   
  ³ÐÀº ¶æÀ¸·Î´Â Ãâ»ý¿¡¼­ºÎÅ͠û³â±â¿¡ µé¾î°¡±â Á÷Àü±îÁö, Áï 12~13¼¼°æ±îÁö¸¦ ¸»ÇÑ´Ù. À°Ã¼ÀûÀ¸·Îµµ Á¤½ÅÀûÀ¸·Îµµ ¼ºÀå¹ßÀ°Çϰí Àִ ½Ã±âÀÇ Àΰ£À» ÃÑÄªÇØ¼­ ¾î¸°À̠ȤÀº ¼Ò¾Æ¶ó°í Çϸç ÀÌ ½Ã±â¸¦ ¸»ÇÑ´Ù. ´Þ·Â ¿¬·É¿¡ µû¶ó¼­ Ãâ»ý Àü±â, Ãâ»ý¿¡¼­ 4ÁÖ°£À» ½Å»ý¾Æ±â, ±× ½Å»ý¾Æ±â¸¦ Æ÷ÇÔÇØ¼­ »ýÈÄ 1³â±îÁö°¡ ¿µ¾Æ±â, »ýÈÄ 1³â ÀÌÈĺÎÅÍ ÃëÇРÀü±îÁöÀÇ ½Ã±â¸¦ À¯¾Æ±â, ÃëÇРÈĺÎÅÍ ÃʵîÇб³ Á¹¾÷±îÁöÀÇ 6~12¼¼ÀÇ ½Ã±â¸¦ Çе¿±â, ¿©¾Æ¿¡¼­´Â 10~18¼¼±îÁö, ³²¾Æ¿¡¼­´Â 12~20¼¼±îÁö¸¦ »çÃá±â¶ó°í ÇÑ´Ù.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • childhood
    ¼Ò¾Æ±â, ¾Æµ¿±â
  • childhood anxiety disorder
    ¼Ò¾ÆºÒ¾ÈÀå¾Ö
  • childhood febrile seizure
    ¼Ò¾Æ±â¿­¹ßÀÛ
  • childhood onset schizophrenia
    ¼Ò¾Æ±â¹ßº´Á¤½ÅºÐ¿­º´
  • childhood schizophrenia
    ¼Ò¾Æ±âÁ¤½ÅºÐ¿­º´
  • antibody half-life
    Ç×ü¹Ý°¨±â
  • average life expectancy
    Æò±Õ¿©¸í
  • advanced cardiac life support
    »ó±Þ½ÉÀå¼Ò»ý¼ú, Àü¹®½ÉÀå¼Ò»ý¼ú
  • advanced pediatric life support
    »ó±Þ¼Ò¾Æ¼Ò»ý¼ú, Àü¹®¼Ò¾Æ¼Ò»ý¼ú
  • advanced trauma life support
    »ó±Þ¿Ü»ó¼Ò»ý¼ú, Àü¹®¿Ü»ó¼Ò»ý¼ú
  • basic life support
    ±âº»¼Ò»ý¼ú
  • basic trauma life support
    ±âº»¿Ü»ó¼Ò»ý¼ú
  • biologic half-life
    »ý¹°ÇÐÀû¹Ý°¨±â
  • biological half life
    »ý¹°ÇÐÀû¹Ý°¨±â
  • half-life
    ¹Ý°¨±â
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 11 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • childhood
    ¾Æµ¿±â, ¼Ò¾Æ±â
  • childhood anxiety disorder
    ¼Ò¾ÆºÒ¾ÈÀå¾Ö
  • life style disease
    »ýȰ½À°üº´
  • half-life
    ¹Ý°¨±â
  • life
    »ýȰ
  • Gram-negative bacteremia
    ±×¶÷À½¼º±ÕÇ÷Áõ
  • negative nitrogen balance
    À½¼ºÁú¼ÒÆòÇü
  • false-negative
    °ÅÁþÀ½¼º
  • negative pressure
    À½¾Ð
  • negative symptom
    À½¼ºÁõ»ó
  • negative transference
    ºÎÁ¤ÀüÀÌ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • childhood
    ¾Æµ¿±â, ¼Ò¾Æ±â
  • childhood schizophrenia
    ¼Ò¾ÆÁ¤½ÅºÐ¿­º´
  • childhood febrile seizure
    ¼Ò¾Æ¿­¹ßÀÛ, ¼Ò¾Æ¿­¼º°æ·Ã
  • childhood onset schizophrenia
    ¾Æµ¿±â¹ßº´Á¤½ÅºÐ¿­º´
  • abridged life table
    °£ÀÌ»ý¸íÇ¥
  • aerospace life support system
    ¿ìÁÖ»ý¸íÀ¯Áö°èÅë
  • antibody half-life
    Ç×ü¹Ý°¨±â
  • average life expectancy
    Æò±Õ±â´ë¿©¸í
  • basic life support
    ±âº»¼Ò»ý¼ú
  • biological half life
    »ý¹°ÇÐÀû¹Ý°¨±â
  • complete life table
    ¿ÏÀü»ý¸íÇ¥
  • corrected life birth rate
    Á¤Á¤Ãâ»ý·ü
  • cycle life
    »ýȰ»ç, »ýȰÁÖ±â
  • life cycle
    »ýȰÁÖ±â, »ýȰ°í¸®
  • sylvatic life cycle
    ¾ß»ý»ýȰÁÖ±â
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • SRE, Schedule of Recent Event
    ÃÖ±Ù»ç°Ç¿¡ ´ëÇÑ ¸ñ·Ï
  • adverse event
    À¯ÇØ»ç·Ê(êóúªÞÀçÓ).
  • granulomatous disease of childhood
    ¼Ò¾ÆÀ°¾ÆÁ¾¼º Áúȯ.
  • granulomatous disease of childhood
    ¼Ò¾Æ À°¾ÆÁ¾¼º Áúȯ
  • independent event
    µ¶¸³»ç»ó(ËÄËöË×Ë×).
  • indian childhood cirrhosis
    Àεµ¼Ò¾Æ°£°æº¯Áõ(ìÔÓøá³ä® Ìãܨñø)?
  • abridged life table
    °£ÀÌ»ý¸íÇ¥(˧ËöË×ËḬ̂).
  • advanced cardiac life support
    ÀÌÂ÷ (½ÉÆó)¼Ò»ý¼ú
  • advanced trauma life support
    »ó±Þ ¿Ü»ó¼Ò»ý¼ú
  • aerospace life support system
    (Ç×°ø)¿ìÁÖ¿ë »ý¸íÀ¯Áö½Ã½ºÅÛ.
  • antibody half-life
    Ç×ü¹Ý°¨±â(ù÷ô÷ÚâÊïÑ¢).
  • half-life
    ¹Ý°¨±â
  • phase of life problem
    ÀλýÁÖ±âÀÇ ¹®Á¦
  • physical half life
    ¹°¸®Àû ¹Ý°¨±â(ÚªìµîÜ ÚâÊõÑ¢).
  • physical half-life
    ¹°¸®Àû¹Ý°¨±â
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • adverse event
    À¯ÇØ»ç·Ê(êóúªÞÀçÓ).
  • cardiac event
    ½É(Àå)»ç°Ç(ãýíõÞÀËì)
  • compound event
    º´ÀÇ º¹ÇÕ»ç°Ç(ËÓ̰Ë×˧).
  • energy deposition event
    ¿¡³ÊÁöºÎ¿©Çö»ó
  • event
    »ç°Ç(Ë×˧).
  • event-related potential
    »ç°Ç°ü·ÃÀüÀ§(ÞÀËìμ֤ï³êÈ)
  • independent event
    µ¶¸³»ç»ó(ËÄËöË×Ë×).
  • benign partial epilepsy of childhood
    ¼Ò¾Æ±â ¾ç¼ººÎºÐ°£Áú
  • childhood
    ¾Æµ¿±â, ¼Ò¾Æ±â.
  • childhood absence epilepsy
    ¼Ò¾Æ±â °á½Å¹ßÀÛ
  • childhood depression
    ¼Ò¾Æ±â ¿ì¿ïÁõ(º´)
  • childhood disintegrative disorder
    ¼Ò¾Æ±â ºØ±«¼º Àå¾Ö
  • childhood eczema
    ¼Ò¾Æ½ÀÁø
  • childhood febrile seizure
    ¼Ò¾Æ¿­¼º°æ·Ã.
  • childhood or adolescence antisocial behavior
    ¼Ò¾Æ±â ȤÀº û¼Ò³â±â ¹Ý»çȸ¼º Çൿ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 4 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • egg negative conversion rate
    Ãæ¶õÀ½ÀüÀ²
  • life cycle
    »ýȰ»ç
  • negative binomial distribution
    ºÎÀÌÇ×ºÐÆ÷
  • sylvatic life cycle
    ¹Ð¸²»ýȰȯ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • biological half-life
    »ý¹°ÇÐÀû ¹Ý°¨±â(ßæÚªùÊîÜÚâÊõÑ¢)
  • effective half-life
    À¯È¿ ¹Ý°¨±â(êóüùÚâÊõÑ¢)
  • half-life
    ¹Ý°¨±â(ÚâÊõÑ¢)
  • life cycle
    "»ýȰ»ç(ßæüÀÞÈ),»ýȰÁÖ±â(ßæüÀñÎÑ¢)"
  • physical half-life
    ¹°¸®Àû ¹Ý°¨±â(Úª×âîÜÚâÊõÑ¢)
  • radioactive half-life
    ¹æ»ç¼º ¹Ý°¨±â(Û¯ÞÒàõÚâÊõÑ¢)
  • DNA-negative mutant
    ¹«(Ùí)DNA º¯ÀÌü(ܨì¶ô÷)
  • negative catalysis
    ¿ªÃ˸ÅÀÛ¿ë(æ½õºØÚíÂéÄ)
  • negative complementation
    ¿ª»óº¸(æ½ßÓÜÍ)
  • negative control
    À½Á¦¾î(ëäð¤åÙ)
  • negative cooperativity
    À½Çùµ¿¼º(ëäúðÔÒàõ)
  • negative effector
    À½ÀÛµ¿ÀÚ(ëäíÂÔÑí­)
  • negative electron
    À½ÀüÀÚ(ëäï³í­)
  • negative feedback
    À½¼º(ëäàõ)µÇ¸ÔÀÓ
  • negative gene control
    À½À¯ÀüÀÚÁ¦¾î(ëäë¶îîí­ð¤åÙ)
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 13 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • childhood
    ¾Æµ¿±â, ¼Ò¾Æ±â
  • false negative
    °¡À½¼º
  • gram negative
    ±×·¥À½¼º
  • negative
    °ÅºÎÀÇ, ºÎÁ¤ÀÇ, À½¼º, ºÎ
  • negative charge
    À½ÇÏÀü, À½ÀüÇÏ
  • negative contrast medium
    À½¼ºÁ¶¿µÁ¦
  • biological half life
    »ý¹°ÇÐÀû¹Ý°¨±â
  • effective half life
    À¯È¿¹Ý°¨±â
  • elimination half-life
    ¼Ò½Ç¹Ý°¨±â
  • half-life; half-time
    ¹Ý°¨±â
  • life cycle
    »ýȰȯ, »ýȰ ÁÖ±â
  • life threatening
    »ý¸íÀ» À§ÇùÇÏ´Â
  • physical half-life
    ¹°¸®Àû ¹Ý°¨±â
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
ECG Electro-Cardio-Graphy(-Gram); ½ÉÀüµµ
   = EKG
  1. Conducting System Structu...
STANDOUT soft thresholding and depth cueing of unspecified techniques
URD unspecified respiratory disease; upper respiratory disease
ALTE Apparent Life-Threatening Event; »ý¸í À§Çù »ç°Ç
  = Near Miss
  ; È£Èí Á¤Áö¿Í ºó¸Æ, û»ö...
ALCEQ Adolescent Life Change Event Questionnaire
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
ALTE Apparent Life Threatening Event
ADE Adverse Drug Event
AERP Auditory Event-Related Potentials
ALSPAC Avon Longitudinal Study of Pregnancy and Childhood
BCECT Benign Childhood Epilepsy with Centrotemporal Spike
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 1 ÆäÀÌÁö: 1
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
  • Z61.9
    Negative life event in childhood, unspecified
    »ó¼¼ºÒ¸íÀÇ ¼Ò¾Æ±âÀÇ ºÎÁ¤Àû ÀÏ»ó »ç°Ç
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • unspecified
    ºñƯÀ̼º
    ´Ù¸¥ °ÍÇÏ°í¸¸ Ưº°È÷ °áÇÕÀ» ÇÑ´ÙµçÁö ¹ÝÀÀÇϴ ƯÀ̼ºÀÌ ¾ø´Â.
  • adverse event
    À¯ÇØ »ç·Ê
  • doping : the action of administering a drug to someone before a sports event
    originally to a horse before a race
    ; the substance thus administered.
  • perceptual event
    Áö°¢ »ç°Ç
  • precipitating event
    ÃËÁø »ç°Ç, ħ°­ »ç°Ç
  • childhood
    ¼Ò¾Æ, ¼Ò¾Æ±â, ¾Æµ¿±â
    Ãâ»ý½Ã~ ¸¸ 15¼¼.
  • childhood depression
    ¼Ò¾Æ±â ¿ì¿ïÁõ, ¼Ò¾Æ±â ¿ì¿ïº´
  • childhood disintegrative disorder
    ¼Ò¾Æ±â ºØ±«¼º Àå¾Ö
  • childhood febrile seizure
    ¼Ò¾Æ ¿­¼º °æ·Ã
  • childhood psychosis
    ¼Ò¾Æ±â Á¤½Åº´, ¼Ò¾Æ±â Á¤½Åº´Áõ
  • chronic bullous dermatosis of childhood
    ¸¸¼º ¼Ò¾Æ ¼öÆ÷¼º ÇǺκ´
  • early childhood
    Ãʱ⠾Ƶ¿±â
    ¸¸ 1-6¼¼ ±îÁöÀÇ ½Ã±â.
  • schizophrenia of childhood type
    ¾Æµ¿Çü Á¤½Å ºÐ¿­Áõ
    »çÃá±â¿¡ ¹ßº´ÇÏ´Â Á¤½Å ºÐ¿­ÁõÀ¸·Î¼­ ÀÚÆó¼º, ³»Ç⼺, ºñÁ¤ÇüÀû ÇൿÀ» Ư¡À¸·Î ÇÑ´Ù.
  • coagulase-negative staphylococcus
    ÄھƱֶóÁ¦ À½¼º Æ÷µµ ±¸±Õ
  • enteric gram-negative bacilli
    Àå³» ±×¶÷ À½¼º °£±Õ
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
adverse event A toxic reaction to a medical therapy.
(09 Oct 1997)
vertical displacement event Disruption which occurs because plasma is not adequately stabilised against vertical motions.
(09 Oct 1997)
event, adverse In pharmacology, an adverse event is any unexpected or dangerous reaction to a drug.
(12 Dec 1998)
event-related potentials, p300 A late-appearing component of the event-related potential. P stands for positive voltage potential and 300 represents 300 millisecond poststimulus. Its amplitude increases with unpredictable, unlikely, or highly significant stimuli and thereby constitutes an index of mental activity.
(12 Dec 1998)
avoidant disorder of childhood A mental disorder occurring in childhood or adolescence characterised by an excessive shrinking away from contact with people who are unfamiliar.
Synonym: avoidant disorder of adolescence.
(05 Mar 2000)
benign childhood epilepsy with centrotemporal spikes A specific epilepsy syndrome beginning in childhood and remitting in adolescence, characterised by nocturnal simple partial motor seizures or generalised tonic-clonic seizures. EEG shows centrotemporal spikes that are activated by sleep and an otherwise normal EEG background.
(05 Mar 2000)
papular acrodermatitis of childhood <syndrome> A cutaneous manifestation of hepatitis B infection occurring in young children; an exanthem comprised of dusky papules on the legs, buttocks, and extensors of the arms; it lasts 2 to 8 weeks and is associated with adenopathy and malaise.
Synonym: papular acrodermatitis of childhood.
(05 Mar 2000)
recurrent pneumonia in childhood <radiology> IMMUNE PROBLEMS, immune deficiency, chronic granulomatous disease of childhood, alpha-1 antitrypsin deficiency, ASPIRATION, GE reflux, H-type TE fistula, disorder of swallowing, oesophageal obstruction, UNDERLYING LUNG DISEASE, sequestration, brochopulmonary dysplasia, cystic fibrosis, atopic asthma, bronchiolitis obliterans, sinusitis, bronchiectasis, ciliary dysmotility syndromes, pulmonary foreign body
(12 Dec 1998)
recurring digital fibromas of childhood Multiple fibrous flesh-coloured nodules on the extensor aspect of the terminal phalanges of adjacent digits of infants and young children which often recur after attempted excision, do not metastasize, and may spontaneously regress in two to three years; composed of spindle cells containing cytoplasmic inclusions believed to be derived from myofibrils.
Synonym: infantile digital fibromatosis.
(05 Mar 2000)
mental disorders diagnosed in childhood Those psychiatric disorders usually first diagnosed in infancy, childhood, or adolescence. These disorders can also be first diagnosed during other life stages.
(12 Dec 1998)
childhood The period of life between infancy and puberty.
(05 Mar 2000)
childhood absence epilepsy A generalised epilepsy syndrome characterised by the onset of absence seizures in childhood, typically at age six or seven years. There is a strong genetic predisposition and girls are affected more often than boys. EEG reveals generalised 3 Hz spike-wave activity on a normal background. Prognosis for remission is good if the patient does not also have generalised tonic-clonic seizures.
See: absence.
Synonym: petit mal epilepsy, pyknolepsy.
(05 Mar 2000)
childhood epilepsy with occipital paroxysms A benign epilepsy syndrome characterised by frequent occipital spikes often activated by eye closure. It has a seizure semiology that includes visual manifestations; not always remitting later in life.
(05 Mar 2000)
childhood muscular dystrophy The most common childhood muscular dystrophy, with onset usually before age 6. Characterised by symmetrical weakness and wasting of first the pelvic and crural muscles and then the pectoral and proximal upper extremity muscles; pseudohypertrophy of some muscles, especially the calf; heart involvement; sometimes mild mental retardation; progressive course and early death, usually in adolescence. X-linked inheritance (affects males and transmitted by females).
Synonym: childhood muscular dystrophy, Duchenne's disease, pseudohypertrophic muscular dystrophy.
(05 Mar 2000)
childhood schizophrenia A severe emotional disturbance of childhood characterised by qualitative impairment in reciprocal social interaction and in communication, language, and social development.
Synonym: autistic disorder, childhood schizophrenia, early infantile autism, Kanner's syndrome.
(05 Mar 2000)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • unspecified
    Ư±â
  • childhood
    À¯³â½Ã´ë
  • childhood
    ¾î¸°½ÃÀý;À¯³â ½Ã´ë;À¯³â;(»ç¹° ¹ß´ÞÀÇ )Ãʱ⠴ܰè
  • second childhood
    ¸Á·É;³ë¸Á
  • event
    »ç°Ç,°á°ú
  • event
    »ç°Ç;Å« »ç°Ç;°æ°ú;°á°ú;°æ¿ì;Á¾¸ñ;½ÃÇÕ(at all events Á¿찣,ÇÏ¿©Æ°,in any event ¹«½¼ ÀÏÀÌ À־,ÇÏ¿©Æ°)
  • field event
    ÇÊµå °æ±â
  • happy event
    °æ»ç;(ƯÈ÷)Ãâ»ê;ź»ý 9
  • main event
    ÁÖ¿ä °æ±â
  • media event
    (¸Å½ºÄÄ º¸µµ¸¦ ¿¹»óÇÏ¿©) Â¥¿©Áø »ç°Ç(Çà»ç);(¸Å½ºÄÄ¿¡ È®´ë(°ú´ë) º¸µµµÈ);Á¶ÀÛµÈ Å« »ç°Ç
  • Rh negative
    RhÀ½¼ºÀÇ Ç÷¾×(»ç¶÷)
  • Rh-negative
    (Ç÷¾×ÀÌ)RhÀ½¼ºÀÇ;RhÀÎÀÚ°¡ ¾ø´Â
  • double negative
    2Áß ºÎÁ¤
  • negative
    ºÎÁ¤(ºÎÀÎ)ÀÇ;ºÎÁ¤ÀûÀÎ;°ÅºÎÀûÀÎ;¹Ý´ëÀÇ;Àû±Ø¼ºÀÌ ¾ø´Â;¼Ò±ØÀûÀÎ;È¿°ú°¡ ¾ø´Â;¾µ¸ð¾ø´Â;À½ÀÇ ¸¶À̳ʽºÀÇ;À½¼ºÀÇ;À½Àü±âÀÇ(¸¦ ÀÏÀ¸Å°´Â);À½È­ÀÇ
  • negative
    ºÎÁ¤¾î;ºÎÁ¤ ¸íÁ¦;°ÅºÎ;°ÅÀý;ºÎÁ¤ÀÇ ¸»(ȸ´ä);°ÅºÎ±Ç(veto);(ÀÏ,¼º°ÝµîÀÇ)¼Ò±Ø¼º;ºÎÁ¤Àû Ãø¸é;(¼ö)À½¼ö;(Àü)À½Àü±â;(Àü±âÀÇ)À½±ØÆÇ;¿øÆÇ;À½È­
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 1
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 1
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 1
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 1
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 1
ÅëÇÕ°Ë»ö ¿Ï·á